1. A combination of (a) an immunoconjugate comprising at least one antigen binding moiety and the effector moiety, and (b) an antibody developed to increase the effector function, for use in treating a disease in a subject in need etom.2. A combination according to claim 1, wherein the effector moiety is a tsitokin.3. A combination according to claim 1, wherein the effector moiety is a cytokine selected from the group consisting of IL-2, GM-CSF, IFN-α and IL-12.4. A combination according to claim 1, wherein the effector moiety is an IL-2.5. The combination of claim 4, wherein the effector moiety IL-2 is the effector moiety mutant IL-2 containing at least one amino acid mutation, in particular amino acid substitution which reduces or eliminates the affinity of the effector groups mutant IL-2 to the α-subunit IL-2 receptor, but retains affinity effector groups mutant IL-2 to the IL-2 intermediate affinity receptor with a comparison with an effector moiety unmutated IL-2.6. A combination according to claim 1, wherein the antigen-binding moiety is an antibody or fragment antitela.7. A combination according to claim 1, wherein the antigen is selected from the group of the molecule and Fab-scFv-molekuly.8. A combination according to claim 1, wherein the immunoconjugate comprises first and second antigen binding gruppirovki.9. A combination according to claim 8, wherein each of said first and second antigen-binding groups is a Fab-molekulu.10. The combination of claim 8, wherein the effector group has a total amino or carboxy terminal peptide bond to the first antigen group and1. Комбинация (а) иммуноконъюгата, содержащего по меньшей мере одну антигенсвязывающую группировку и эффекторную группировку, и (б) антитела, разработанного для увеличения эффекторной функции, для применения в лечении заболевания у индивидуума, нуждающегося в этом.2. Комбинация по п.1, в которой эффекторная группировка представляет собой цитокин.3. Комбинация по п.1, в которой эффекторная группировка
